Cancer Testes Antigens in Breast Cancer: Biological Role, Regulation, and Therapeutic Applicability

REFERENCES

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5): 23.
   Google Scholar
• http://www.cancer.gov/cancertopics/types/breast.
   Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. GLOBOCAN 2008;2008:1.2.
   Google Scholar
• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Chapman C, Murray A, Chakrabarti J, Autoantibodies in breast cancer: their use as an aid to early diagnosis. Anal Oncol. 2007;18(5):868–873.
   PubMed Web of Science ®Google Scholar
• Gilbert Welch H, M, MPH, Fankel BA . Likelihood that a woman with screen-detected breast cancer has her “Life saved” by that screening. Arch Intern Med. 2011;171(22):2043–2046.
   PubMedGoogle Scholar
• http://emedicine.medscape.com/article/1945498-overview#aw2aab6b5.
   Google Scholar
• Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146(7):502–510.
   PubMed Web of Science ®Google Scholar
• http://emedicine.medscape.com/article/1947145-treatment.
   Google Scholar
• Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer. 2008;8(4):324–333.
   PubMedGoogle Scholar
• University of Texas M. D. Anderson Cancer Center. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence. Sci Daily. 2008, December 24.
   Google Scholar
• van der Bruggen P, Traversari C, Chomez, P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643–1647.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M. Clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond. Int Rev Immun. 2011;30:138–149.
   PubMed Web of Science ®Google Scholar
• Costa FF, Le Blanc K, Brodin B. Concise review cancer/testis antigens, stem cells, and cancer. Stem Cells, 2007(25):707–711.
   PubMedGoogle Scholar
• Knuth A, Wolfel T, Klehmann E, et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl Acad Sci USA. 1989;86: 2804–2808.
   PubMed Web of Science ®Google Scholar
• Boël P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167–175.
   PubMed Web of Science ®Google Scholar
• De Backer O, Arden KC, Boretti M, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 1999;59:3157–3165.
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94: 1914–1918.
   PubMed Web of Science ®Google Scholar
• Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187:1163–1167.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host.. Proc Natl Acad Sci USA. 1995;92:11810–11813.
   PubMed Web of Science ®Google Scholar
• Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucl Acids Res. 2008;37:D816–D819.
   Google Scholar
• Otavia L, Caballero Y-TC. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014–2021.
   PubMedGoogle Scholar
• Simpson AJ, Caballero OL, Jungbluth A, , Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615–625.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iranian Med. 2009;12(4):395–404.
   PubMedGoogle Scholar
• Wang MG, ZR, Yi H, Rosenberg S, Localization of MAGE gene encoding a human melanoma antigen to chromosome Xq28. Cytogenet Cell Genet. 1994;67(2):116–119.
   PubMedGoogle Scholar
• Grigoriadis A, Caballero OL, Hoek KS, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA. 2009;106(32):1393–13498.
   Google Scholar
• Doyle JM, Gao J, Wang J, MAGE-RING protein complexes comprise a family of E3 ubiquitn ligases. Mol Cell Biol. 2010;39(6):963–974.
   Google Scholar
• Anelika Burger YA, Richard K, Arun KS. Novel RING E3 ubiqutin ligases in breast cancer. Neoplasia. 2006;8(8):689–695.
   PubMedGoogle Scholar
• Sandra Laduron RD, Sifang Z, Olga K, MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucl Acids Res. 2004;32(14):4340–4350.
   PubMedGoogle Scholar
• Martin Monte MS, Leticia YP, Bublik DR, MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 2006;103(30):11160–11165.
   PubMedGoogle Scholar
• Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-a cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010;70:10362–10370.
   PubMedGoogle Scholar
• Aprelikova O, Pandolfi S, Tackett S, Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res. 2009;69(2):616–624.
   PubMed Web of Science ®Google Scholar
• Lian Y, Sang M, Ding C, , Expressions of MAGE A10 and MAGE A11 in breast cancers and their prognostic significance: a retrospective clinical study. J Can Res Clin Oncol. 2012;138(3):519–527.
   PubMedGoogle Scholar
• Tahara K, Mori M, Sadanaga N, Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999;85(6):1234–1240.
   PubMed Web of Science ®Google Scholar
• Tsai JR, Chong IW, Chen YH, et al. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer. 2007;56(2):185–192.
   PubMed Web of Science ®Google Scholar
• Nagao T, Higashitsuji H, Nonoguchi K, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem. 2003;278(12):10668–10674.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Itoh K, Higashitsuji H, et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem. 2004;279(15):15505–15514.
   Google Scholar
• Bandić D, Juretić A, Šarčević B, et al. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer. Croat Med J. 2006;47:32–41.
   PubMedGoogle Scholar
• Cho HJ, Caballero OL, Gnjatic S, Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immunol. 2006;6(12).
   PubMedGoogle Scholar
• Sugita Y, Wada H, Fujita S, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004;64:2199–2204.
   PubMed Web of Science ®Google Scholar
• Theurillat JP, Ingold F, Frei C, et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer. 2007;120:2411–2417.
   PubMedGoogle Scholar
• Richardson RT, Yamasaki N, O'Rand MG, Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction. Dev Biol. 1994;165(2):688–701.
   PubMedGoogle Scholar
• Kong M, Richardson RT, Widgren EE, et al.. Sequence and localization of the mouse sperm autoantigenic protein, Sp17. Biol Reprod. 1995;53(5):579–590.
   PubMedGoogle Scholar
• Dong G, Loukinova E, Smith CW, , Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem. 1997;28–29:90–100.
   Google Scholar
• Chiriva-Internati M, Wang Z, Xue Y, Spermprotein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol. 2001;31:2277–2283.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E, Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer. 2002;94:2447–2453.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Grizzi F, Weidanz JA, A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007;321(1–2):86–93.
   PubMedGoogle Scholar
• Lea IA, Widgren EE, O'Rand MG. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol. 2004;2:57.
   PubMedGoogle Scholar
• Kausar T, Ahsan A, Hasan MR, Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2010;126:1494–1503.
   PubMedGoogle Scholar
• Li FQ, Han YL, Liu Q, Overexpression of human spermprotein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer. 2009;9:323.
   PubMedGoogle Scholar
• Chen Y, Wang Y, Yu H, The cross talk between protein kinase A- and RhoA-mediated signaling in cancer cells. 2005;230(10):731–741.
   Google Scholar
• Shan J, Yuan L, Xiao Q, TSP50, a possible protease in human testes, is activated in breast cancer of epithelial cells. Cancer Res. 2002;62(1):290–294.
   PubMed Web of Science ®Google Scholar
• Song ZB, Bao YL, Zhang Y, Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the nuclear factor κB (NF-κB) signalling pathway. Biochem J. 2011;436(2):457–467.
   PubMedGoogle Scholar
• D'Arcy V, Pore N, Docquier F, BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer. 2008;98:571–579.
   PubMedGoogle Scholar
• Hong JA, Kang Y, Abdullaev Z, Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005;65:7763–7774.
   PubMed Web of Science ®Google Scholar
• Vatolin S, Abdullaev Z, Pack SD, Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res. 2005;65:7751–7762.
   PubMed Web of Science ®Google Scholar
• Dougherty CJ, Ichim TE, Liu L, et al. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Res Commun. 2008;370(1):109–112.
   PubMedGoogle Scholar
• Chen J, Rappsilber J, Chiang YC, et al. Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complex. J Mol Biol. 2001;14(4):683–694.
   Google Scholar
• Ajiro M, Katagiri T, Ueda K, et al. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Cancer. 2009;35(4):673–681.
   Google Scholar
• http://www.cta.lncc.br/modelo.php.
   Google Scholar
• Cheng YH, Wong EW, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 2011;1(3):209–220.
   PubMedGoogle Scholar
• http:// www.medterms.com/script/main/art.asp?articlekey=21819.
   Google Scholar
• Kosaka-Suzuki N, Suzuki T, Pugacheva EM, et al. Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter. J Biol Chem. 2011;286(31):27378–27388.
   PubMedGoogle Scholar
• Wang M, Bao YL, Wu Y, et al. Basic FGF downregulates TSP50 expression via the ERK/Sp1 pathway. J Cell Biochem. 2010;111(1):75–81.
   PubMedGoogle Scholar
• Xu H, Shan J, Jurukovski V, TSP 50 encodes a testis-specific protease and is negatively regulated by p53. Cancer Res. 2007;67(3):1239–1245.
   PubMed Web of Science ®Google Scholar
• Yao-Tseng C, Ross DS, Chiu R, et al. Multiple cancer/ testis antigens are preferentially expressed in hormone- receptor negative and high grade breast cancers. PLOS ONE. 2011;6(3):e17876.
   Google Scholar
• Curigliano G, Viale G, Ghioni M, Cancer testis antigen expression in triple negative breast cancer. Ann Oncol. 2010;22(1):98–103.
   PubMedGoogle Scholar
• Adams S, Greeder L, Reich E, Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother. 2011;60(7):999–1007.
   PubMed Web of Science ®Google Scholar
• Tanja BC, Giulio S, Antonio J, High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med Oncol. 2012;29(3):1586–1591.
   PubMed Web of Science ®Google Scholar
• Mischo A, Kubuschok B, Ertan K, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer. 2006;118(3):696–703.
   PubMed Web of Science ®Google Scholar
• Taylor M, Bolton LM, Johnson, P, Breast cancer is promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res. 2007;9(4):R46.
   Google Scholar
• Mkrtichyan M, Ghochikyan A, Davtyan, H, Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol. 2011;270(2):188–197.
   PubMedGoogle Scholar
• Ghochikyan A, Mkrtichyan M, Loukinov D, Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol. 2007;178(1):566–573.
   PubMedGoogle Scholar
• Loukinov D, Ghochikyan A, Mkrtichyan M, Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem. 2006;98(5):1037–1043.
   PubMedGoogle Scholar
• Mkrtichyan M, Ghochikyan A, Loukinov D, DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther. 2008;15(1):61–64.
   PubMedGoogle Scholar
• http: //www.immun-immed.org/Breast_cancer.html#
   Google Scholar
• Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 2003;194(3):272–288.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis-Filho JS. Histolgical and molecular types of breast cancer: is there a unifying taxonomy. Natl Rev Clin Oncol. 2009;6(12):718–730.
   PubMed Web of Science ®Google Scholar